New Alzheimer's drug approved in U.S. despite concerns about effectiveness

U.S. government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease.

The U.S. Food and Drug Administration (FDA) said it approved the drug from Biogen based on results that seemed “reasonably likely” to benefit Alzheimer’s patients.

It’s the only therapy that U.S. regulators have said can likely treat the underlying disease, rather than manage symptoms like

This story was originally published on  CBC News. To read the rest of this news worthy story, please visit https://www.cbc.ca/news/health/fda-approves-alzheimers-drug-1.6056149?cmp=rss.

This post was originally published on this site